ARK Genomic Revolution ETF (BATS:ARKG) Sets New 1-Year High – Still a Buy?

ARK Genomic Revolution ETF (BATS:ARKG) reached a new 52-week high during trading on Monday . The stock traded as high as $44.53 and last traded at $44.44, with a volume of 1245037 shares traded. The stock had previously closed at $43.04.

ARK Genomic Revolution ETF Stock Up 2.9%

The firm’s 50 day simple moving average is $38.55 and its 200 day simple moving average is $32.48.

Institutional Trading of ARK Genomic Revolution ETF

Large investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. boosted its position in ARK Genomic Revolution ETF by 30.6% during the 4th quarter. JPMorgan Chase & Co. now owns 5,149,454 shares of the company’s stock worth $149,180,000 after acquiring an additional 1,205,541 shares during the period. Morgan Stanley increased its holdings in shares of ARK Genomic Revolution ETF by 42.2% during the fourth quarter. Morgan Stanley now owns 4,025,965 shares of the company’s stock valued at $116,632,000 after purchasing an additional 1,193,795 shares during the period. BNP Paribas Financial Markets raised its stake in shares of ARK Genomic Revolution ETF by 49.7% during the fourth quarter. BNP Paribas Financial Markets now owns 3,514,980 shares of the company’s stock valued at $101,829,000 after purchasing an additional 1,167,558 shares in the last quarter. Wells Fargo & Company MN raised its stake in shares of ARK Genomic Revolution ETF by 29.1% during the fourth quarter. Wells Fargo & Company MN now owns 1,287,390 shares of the company’s stock valued at $37,296,000 after purchasing an additional 290,301 shares in the last quarter. Finally, Royal Bank of Canada lifted its holdings in ARK Genomic Revolution ETF by 185.0% in the fourth quarter. Royal Bank of Canada now owns 445,592 shares of the company’s stock worth $12,910,000 after purchasing an additional 289,237 shares during the period.

ARK Genomic Revolution ETF Company Profile

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.